Pfizer sold its $3 billion stake in Haleon

Pfizer Sells $700M Stake in Haleon, Trimming Ownership to 7.3%
On Jan 15, Pfizer Inc. ( PFE, Financial) announced to sale of about 700 million ordinary shares of Haleon plc through a secondary offering. The sale is 7.7% of Haleon's issued share capital and will be undertaken following an accelerated book-building process dealing with institutional investors.
Pfizer Sells 700 Million Haleon Shares for $3.05 Billion
The sale decreases Pfizer’s shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from 15%.
Pfizer to sell $3 billion stake in Sensodyne maker Haleon
Pfizer will sell shares worth 2.50 billion pounds ($3.05 billion) in Haleon, lowering its stake in the British consumer healthcare company to about 7.3% from 15%, its bookrunner JPMorgan said on Wednesday.
Pfizer Further Pares Haleon Stake With £2.5 Billion Sale
Pfizer Inc. sold about 700 million shares in Haleon Plc, further paring its stake in the maker of Sensodyne toothpaste.Most Read from BloombergThese Homes Withstood the LA Fires. Architects Explain WhyAs E-Bikes Boom in NYC,
Pfizer to sell 700M ordinary shares of Haleon
Pfizer (PFE) announces that it intends to sell approximately 700M ordinary shares in Haleon plc (HLN), representing approximately 7.7% of
Pfizer to cut stake in Sensodyne-maker Haleon to 7.3%, says bookrunner
Pfizer is looking to sell about 700 million ordinary shares in Haleon, its bookrunner J.P. Morgan said on Tuesday, lowering its stake in the British consumer healthcare company to about 7.3% from 15%.
Pfizer pares back Haleon stake in £2.5bn sale
Pfizer has further reduced its holding in Haleon, it was confirmed on Wednesday, after the drugs giant offloaded 700m shares in a £2.5bn sale.
Pfizer Sells GBP 2.50 Bln Of Shares In Haleon
Wednesday announced the sale of 700 million shares in Haleon Plc (HLN), a British multinational consumer healthcare
Why Pfizer sold its $3 billion stake in Haleon
Pfizer’s decision to offload $3.05 billion worth of shares in Haleon is a strategic move driven by shifting priorities in a volatile pharmaceutical market. The transaction, involving 700 million shares priced at 357 pence each,
What To Expect From PFE Stock In 2025?
In this note, while we briefly touch upon Pfizer’s performance in 2024, we focus on the impact on PFE stock and how 2025 ...
Bloomberg L.P.3d
Pfizer Further Pares Haleon Stake With Offer to Sell 7.7%
Pfizer Inc. is offering around 700 million shares in Haleon Plc, representing a roughly 7.7% stake in the maker of Sensodyne toothpaste. The deal could raise around £2.6 billion ($3.1 billion ...
London South East4d
PROPOSED OFFERING IN HALEON PLC BY PFIZER INC.
PROPOSED SECONDARY OFFERING OF ORDINARY SHARES IN HALEON PLC BY PFIZER INC. The price per Sale Share will be determined by way of an accelerated bookbuilding process to institutional investors.
devdiscourse3d
Jury Hits Bayer with $100 Million Verdict Over PCB Controversy
A Washington jury ordered Bayer to pay $100 million to individuals sickened by toxic PCBs at a Seattle school, marking the latest courtroom challenge for the company. Meanwhile, Pfizer is reducing its ...